Navigation Links
Novagali Pharma Completes a EUR15 Million Fund Raising

EVRY, France, September 26 /PRNewswire/ -- Novagali Pharma, a French Laboratory specialized in ophthalmology announces today it has secured EUR15 million in a new financing round with the participation of the historical Company investors.

Thanks to this new contribution Novagali Pharma will continue to develop its high potential projects:

- The commercialization in France and abroad of its first

marketable product, Cationorm(R), indicated for the treatment of dry eye


- The development of its flagship products: Vekacia(R) (Vernal

keratoconjunctivitis), Cyclokat(R) (Dry eye), Nova21027 (Glaucoma) and

Cortiject(R) (Diabetic macular edema), and particularly for Cyclokat(R)

the phase III clinical study now in course in Europe and the one

initiated in the United States during the third quarter of 2008 as well

as the phase I finalization in patient with Cortiject(R) started in

April 2008 in the United States.

Jerome Martinez, Novagali Pharma Chief Executive Officer, says: "The total amount of this fund rising strengthens once again our investors confidence to our development strategy, our products and our technological approach. This new source of financing will help us to carry on our company development".

About Novagali Pharma :

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Genopole biocluster in Evry (France).

SOURCE Novagali Pharma SA
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novagali Pharma Announces the Launch of Cationorm(R)
2. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
3. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
4. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
5. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
6. New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
7. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
8. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
9. AIT Laboratories Expands Pharma Services
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing of ... team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific discoveries ... doctors and other healthcare providers face challenges in better ... and patients. In addition, as more children continue to ... patient,s adulthood and old age. John M. ... Children,s Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
Breaking Biology News(10 mins):